Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05056857 · ClinicalTrials.gov registry record
Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen
A clinical trial of Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 290
- Enrollment target
- 1
- Study location
NCT05056857: Recruiting study of Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT05056857 is a study of Breast Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 290 participants, below the 768-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05056857, a study of Breast Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 290 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines the long-term effects of tamoxifen (TAM) treatment on excessive production of neutrophil extracellular traps (NET) and their impact on breast cancer and side effects. NET are produced by the body to fight infections but have also been linked to side effects caused by the body's immune system. Treatment with tamoxifen increases the production of NETs. This study may help researchers determine if the increased number of NETs in the body has a damaging effect in breast cancer.
Primary Outcome
Percent of NET-forming neutrophils is deduced in each sample by quantitative method standardized in the lab.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Electronic Health Record Review
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2026-10-31 |
What NCT05056857 shows while recruiting
NCT05056857 is an observational study that tracks outcomes without assigning an intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap, below the 768-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT05056857 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05056857 about?
NCT05056857 is a clinical study titled "Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen". This study examines the long-term effects of tamoxifen (TAM) treatment on excessive production of neutrophil extracellular traps (NET) and their impact on breast cancer and side effects. NET are produced by the body to fight infections but have also been linked to side effects caused by the body's i...
What is the current status of trial NCT05056857?
This trial is currently recruiting. The enrollment target is 290 participants. The study started on 2021-10-01. Estimated completion is 2026-10-31.
What conditions does trial NCT05056857 study?
This clinical trial studies the following conditions: Breast Carcinoma.
What interventions are being tested in trial NCT05056857?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT05056857?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05056857 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05056857's enrollment target sits among peer trials
290 32nd of 106 higher than 75 of 106 other Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surviving Daily Life
RECRUITING
-
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
RECRUITING
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
RECRUITING
-
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI